The subject of the tender is the conclusion of active ingredient-related discount contracts in accordance with § 130a (8) SGB V for medicinal products for up to 27 months from 01.07.2023 - 30.09.2025. The contracts refer to all contractual medicinal products that are supplied during the term of the contract at the expense of the health insurance companies. In principle, only prescription drugs are in demand per lot. In principle, the tender is based on active ingredients within the meaning of § 24b (2) AMG, not within the meaning of § 4 (19) AMG. 165 lots were formed. These are divided into so-called exchange groups. The DAK-G is authorised by the other substitute funds to carry out the tender in the name of and with effect for them. Further details can be found in the procurement documents.

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the above lot, the intention is to establish discount contracts with up to 2 pharmaceutical entrepreneurs (as

individual bidders or as bidder association (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the above lot, it is intended to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as consortium(s) of pharmaceutical companies)

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

The discount period for lot 212 - TK / hkk / HEK - Bimatoprost - S01EE03 starts on 01.07.2024.

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the above-mentioned lot, the intention is to conclude discount agreements with up to 2 pharmaceutical companies (as individual bidders or as bidding group (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

In the case of the aforementioned lot, the intention is to conclude a discount contract with a pharmaceutical company (as a single bidder or as a group of bidders made up of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).

For the lot mentioned above, the intention is to conclude discount agreements with up to 3 pharmaceutical companies (as individual bidders or as bidding consortium (s) of pharmaceutical companies).